Johnson & Johnson / Actelion

Seeking to bolster its offerings of rare disease treatments, Johnson & Johnson announced the largest deal in its history with a proposed $30 billion buy of Swiss biotechnology company Actelion Ltd. The all-cash deal would give Johnson & Johnson access to Actelion’s medications for high blood pressure, pulmonary arterial hypertension and other rare conditions.